Physician profile
Omid Vahdat
NPI 1033164330
$21,418.22
in general payments reported to CMS, 2019-2025
42 companies · $4,622 in 2025
The $4,622 reported for 2025 was more than what 82% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,466 · 2020: $3,383 · 2021: $2,306 · 2022: $2,388 · 2023: $5,045 · 2024: $2,208 · 2025: $4,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,143 · Travel and Lodging: $3,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,142.67 |
| Travel and Lodging | $3,732.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,817.22 | 2020-2025 | Aveir, Thoratec Heartmate 3 Lvas Implant Kit, Amplatzer Talisman |
| Edwards Lifesciences Corporation | $3,691.28 | 2020-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $1,348.08 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $1,134.86 | 2019-2025 | |
| Pfizer INC. | $1,133.73 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,085.78 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $797.07 | 2019-2025 | Wainua, Farxiga, Brilinta |
| Merck Sharp & Dohme LLC | $752.64 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $674.03 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $659.75 | 2019-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $647.12 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $643.72 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $546.91 | 2019-2025 | Repatha, Repatha, Krystexxa |
| Lilly USA, LLC | $456.89 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amarin Pharma, INC. | $388.01 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omid Vahdat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.